JENNIFER DIETZEL: Open Payments
NPI 1376973073 · SAGINAW, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$826 in 39 payments from 14 companies in 2025. Trend: 2023 $837 · 2024 $803 · 2025 $826
Food & beverage: $826
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 9 | $249 |
| ABBVIE INC. | 4 | $84 |
| Teva Pharmaceuticals USA, Inc. | 3 | $72 |
| Neurocrine BioSciences, Inc. | 4 | $69 |
| Otsuka America Pharmaceutical, Inc. | 3 | $60 |
| Janssen Pharmaceuticals, Inc | 3 | $59 |
| Biogen, Inc. | 2 | $43 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $42 |
| E.R. Squibb & Sons, L.L.C. | 2 | $38 |
| Axsome Therapeutics, Inc. | 2 | $37 |
Products named: ARISTADA, VIVITROL, REXULTI, VRAYLAR, INGREZZA, AUSTEDO XR, ZURZUVAE, CAPLYTA.
Industry payments across MI — which companies pay providers there.
